Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Eplerenone for Central Serous Chorioretinopathy

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Tufts Medical Center
Information provided by (Responsible Party):
Tufts Medical Center Identifier:
First received: March 25, 2013
Last updated: January 24, 2017
Last verified: January 2017
  • The goal of the study is to examine the short-term effects and safety of a systemic anti-aldosterone medication, eplerenone, in a small group of patients with central serous chorioretinopathy (CSCR).
  • There is currently no standard treatment or therapy for either acute or chronic CSCR, a potentially debilitating eye disease.
  • There is evidence in both animals and humans that high blood serum corticosteroid levels can cause or worsen CSCR or findings similar to CSCR in the choroid and retina
  • Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR
  • The investigators' aim is to evaluate a standardized dose of eplerenone in a controlled prospective fashion for both acute and chronic CSCR.
  • The study consists of taking a standard dose of eplerenone, 50mg once daily, for 1 month
  • Over the course of the month, patients will be monitored for side effects, as well as visual and anatomical response to the medication

Condition Intervention Phase
Central Serous Chorioretinopathy
Drug: Eplerenone 50mg
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Eplerenone for Central Serous Chorioretinopathy: A Pilot Study

Resource links provided by NLM:

Further study details as provided by Tufts Medical Center:

Primary Outcome Measures:
  • Resolution of Sub-retinal Fluid [ Time Frame: Baseline and 1 month after treatment ]
    Optical coherence tomography (OCT) is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy

Secondary Outcome Measures:
  • Change in macular thickness [ Time Frame: Baseline and 1 month after treatment ]
    Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared.

  • Best Corrected Visual Acuity [ Time Frame: Baseline and 1 month after treatment ]
    Visual acuity will be measured with standard ETDRS eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid)

  • Change in choroidal thickness, both eyes [ Time Frame: Baseline and 1 month after treatment ]
    Choroidal thickness can be measured using OCT, and is known to be affected in patients with central serous chorioretinopathy. OCT characteristics may be affected in the fellow eye. Thickness of the choroid under the fovea will be manually calculated in both the study eye and the fellow eye.

  • Safety and Tolerability Characteristics [ Time Frame: Baseline and 1 month after treatment ]
    Eplerenone can cause elevation of serum potassium, cholesterol, and LFT's, as well as decrease the blood pressure. After initial screening, serum potassium and creatinine will be evaluated at 1 and 4 weeks after baseline. Additional serum tests of electrolytes, liver function tests, uric acid, and a fasting cholesterol panel will be obtained before treatment and 4 weeks after baseline. Adverse and Serious Adverse Events will be recorded and reported to the Institutional Review Board.

Estimated Enrollment: 20
Study Start Date: May 2013
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eplerenone
All patients in this study will receive Eplerenone 50mg once daily for 4 weeks.
Drug: Eplerenone 50mg
All patients will receive the same dose of eplerenone.
Other Names:
  • Inspra (Pfizer)
  • Eplerenone (Generic)

Detailed Description:
  • The investigators hypothesize that aldosterone inhibition with eplerenone will decrease choroidal vessel vasodilation, focal leakage, and choroidal thickness in patients with both acute and chronic CSCR, leading to resolution of subretinal fluid and ultimately an improvement in symptoms.
  • Resolution of sub-retinal fluid will be the primary outcome, which can be precisely measured using optical coherence tomography (OCT)
  • Secondary outcomes will include: Change in macular thickness measured with OCT, in central macular circle thickness on OCT, change in visual acuity, change in dye leakage characteristics on fluorescein angiography, change in OCT characteristics of the fellow eye, and safety and tolerability characteristics
  • In acute CSCR, subretinal fluid often resolves on its own, but it often takes several months (the literature shows that ~20% of patients have complete resolution of sub-retinal fluid on OCT 1 month after presentation)
  • Chronic CSCR is defined as persistent fluid on OCT after 3 months of symptom onset, or recurrence of signs and symptoms within 1 year after the prior episode
  • In this study, the investigators will not make a distinction between acute and chronic CSCR
  • Eplerenone, a generic medication, is a potassium sparing diuretic, which is FDA approved to treat heart failure as well as high blood pressure, but is not FDA approved for treatment of central serous chorioretinopathy.
  • The most important side effect of eplerenone is elevation of serum potassium and decrease of blood pressure
  • Patients will therefore be screened with routine blood tests as suggested by the package insert of the medication, and serum potassium and blood pressure will be monitored routinely as directed by the medication package insert
  • Study visits will be performed at therapy initiation, 1 week, 2 weeks, and 4 weeks

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18 or over
  2. Ability to give written informed consent
  3. Presence of sub-retinal fluid under the fovea as seen on OCT
  4. Diagnosis of Acute or Chronic CSCR:

    • Acute CSCR: First presentation to eye clinic with visual symptoms, including decreased vision or visual distortion, and the characteristic appearance of CSCR on examination, fluorescein angiography, and OCT.
    • Chronic CSCR: Previous diagnosis of CSCR, persistent subretinal fluid on OCT for more than 3 months after initial presentation to the eye clinic, and <50% reduction in fluid thickness on OCT after 3 months. Patients who have had previous treatment for CSCR may be included.

Exclusion Criteria:

  1. Age less than 18
  2. Persons with impaired decision-making ability.
  3. Women who are known to be pregnant or are actively trying to conceive.
  4. Additional eye disease affecting the macula or posterior retina.
  5. At screening, serum potassium concentration ≥5.0 mEq/L , a serum creatinine concentration >2 mg/dL in men and >1.8 mg/dL in women, or a creatinine clearance <50 mL/min, and during concomitant administration of potassium supplements, potassium-sparing diuretics, and/or potent CYP3A4 inhibitors (amifostine, cyclosporine, fluconazole, itraconazole, ketoconazole, mifepristone, posaconazole, potassium salts, Rituximab, tacrolimus or voriconazole).
  6. Patients with type 2 diabetes will be screened for microalbuminuria with a urinalysis. If microalbuminuria is present, these patients will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01822561

Contact: Andre J Witkin, MD 617-636-7950

United States, Massachusetts
New England Eye Center / Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Andre J Witkin, MD    617-646-7950   
Contact: Carly Satsuma    617-636-5489   
Principal Investigator: Andre J Witkin, MD         
Sub-Investigator: Jay S Duker, MD         
Sub-Investigator: Elias Reichel, MD         
Sub-Investigator: Caroline R Baumal, MD         
Sub-Investigator: Adam R Rogers, MD         
Sub-Investigator: Nadia K Waheed, MD         
Sub-Investigator: Michelle Liang, MD         
Sub-Investigator: Shilpa Desai, MD         
Sponsors and Collaborators
Tufts Medical Center
Principal Investigator: Andre J Witkin, MD Tufts Medical Center
  More Information


Responsible Party: Tufts Medical Center Identifier: NCT01822561     History of Changes
Other Study ID Numbers: NEEC-10722
Study First Received: March 25, 2013
Last Updated: January 24, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Tufts Medical Center:
Central Serous Chorioretinopathy
Optical Coherence Tomography
Enhanced Depth Imaging
Subretinal Fluid

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents processed this record on April 25, 2017